Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients

Full text
Author(s):
Show less -
Avelino-Silva, Vivian Iida [1] ; Miyaji, Karina Takesaki [1] ; Mathias, Augusto [2] ; Costa, Dayane Alves [2] ; de Carvalho Dias, Juliana Zanatta [2] ; Lima, Sheila Barbosa [3] ; Simoes, Marisol [3] ; Freire, Marcos S. [3] ; Caiaffa-Filho, Helio H. [4, 5] ; Hong, Marisa A. [2, 4] ; Lopes, Marta H. [1] ; Sartori, Ana M. [1] ; Kallas, Esper G. [2, 1]
Total Authors: 13
Affiliation:
[1] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo - Brazil
[2] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo - Brazil
[3] Fundacao Oswaldo Cruz Biomanguinhos, Rio De Janeiro - Brazil
[4] Adolfo Lutz Inst, Sao Paulo - Brazil
[5] Univ Sao Paulo, Sch Med, Lab Med Invest LIM 3, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES; v. 71, n. 2, p. 189-195, FEB 1 2016.
Web of Science Citations: 6
Abstract

Background:Yellow fever vaccine (YFV) induces weaker immune responses in HIV-infected individuals. However, little is known about YFV responses among antiretroviral-treated patients and potential immunological predictors of YFV response in this population.Methods:We enrolled 34 antiretroviral therapy (ART)-treated HIV-infected and 58 HIV-uninfected adults who received a single YFV dose to evaluate antibody levels and predictors of immunity, focusing on CD4(+) T-cell count, CD4(+)/CD8(+) ratio, and Human Pegivirus (GBV-C) viremia. Participants with other immunosuppressive conditions were excluded.Results:Median time since YFV was nonsignificantly shorter in HIV-infected participants than in HIV-uninfected participants (42 and 69 months, respectively, P = 0.16). Mean neutralizing antibody (NAb) titers was lower in HIV-infected participants than HIV-uninfected participants (3.3 vs. 3.6 log(10)mIU/mL, P = 0.044), a difference that remained significant after adjustment for age, sex, and time since vaccination (P = 0.024). In HIV-infected participants, lower NAb titers were associated with longer time since YFV (rho: -0.38, P = 0.027) and lower CD4(+)/CD8(+) ratio (rho: 0.42, P = 0.014), but not CD4(+) T-cell count (P = 0.52). None of these factors were associated with NAb titers in HIV-uninfected participant. GBV-C viremia was not associated with difference in NAb titers overall or among HIV-infected participants.Conclusions:ART-treated HIV-infected individuals seem to have impaired and/or less durable responses to YFV than HIV-uninfected individuals, which were associated with lower CD4(+)/CD8(+) ratio, but not with CD4(+) T-cell count. These results supports the notion that low CD4(+)/CD8(+) ratio, a marker linked to persistent immune activation, is a better indicator of functional immune disturbance than CD4(+) T-cell count in patients with successful ART. (AU)

FAPESP's process: 13/05246-8 - IMPACT OF INCIDENT INFECTION BY GBV-C IN CELL ACTIVATION IN PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV).
Grantee:Dayane Alves Costa
Support type: Scholarships in Brazil - Doctorate